Gapping down
In reaction to disappointing earnings/guidance: RDEN -19.4%, BHP -3.4%, (also discloses plans for demerger of selection of assets to simplify portfolio) JMEI -2.7%, PWRD -1.6%.
Other news: ONTY -18.7% (disclosed that Phase 1/2 study of tecemotide in patients with lung cancer did not meet its primary endpoint, no treatment effect seen in secondary endpoints), RIO -1.6% (in sympathy with BHP), PCYC -1.5% (appointed Shawn Cline Tomasello as Chief Commercial Officer), CLR -0.8% (Board declared a 2:1 stock split to be issued in the form of a stock dividend),SLXP -0.8% (Announces Early Termination of HSR Waiting Period for Pending Transaction), S -0.7% (plans to introduce $100 family plan, according to reports).
Analyst comments: LOCO -5.2% (initiated with a Underweight at Morgan Stanley, also initiated with a Hold at Jefferies, initiated with a Neutral at Robert W. Baird), SCTY -1.7% (downgraded to Neutral from Outperform at Robert W. Baird), CEO -0.9% (downgraded to Hold from Buy at Jefferies).
In reaction to disappointing earnings/guidance: RDEN -19.4%, BHP -3.4%, (also discloses plans for demerger of selection of assets to simplify portfolio) JMEI -2.7%, PWRD -1.6%.
Other news: ONTY -18.7% (disclosed that Phase 1/2 study of tecemotide in patients with lung cancer did not meet its primary endpoint, no treatment effect seen in secondary endpoints), RIO -1.6% (in sympathy with BHP), PCYC -1.5% (appointed Shawn Cline Tomasello as Chief Commercial Officer), CLR -0.8% (Board declared a 2:1 stock split to be issued in the form of a stock dividend),SLXP -0.8% (Announces Early Termination of HSR Waiting Period for Pending Transaction), S -0.7% (plans to introduce $100 family plan, according to reports).
Analyst comments: LOCO -5.2% (initiated with a Underweight at Morgan Stanley, also initiated with a Hold at Jefferies, initiated with a Neutral at Robert W. Baird), SCTY -1.7% (downgraded to Neutral from Outperform at Robert W. Baird), CEO -0.9% (downgraded to Hold from Buy at Jefferies).